Develops small-molecule medicines for patients with kidney and metabolic diseases, using genetic research to identify drug targets and guide development.
10-K for FY2025, filed Mar 25, 2026
Maze earns revenue by granting licenses to drug programs to biotechnology companies; agreements can bring upfront payments, milestone payments, and royalties tied to licensed products’ sales.
10-K for FY2025, filed Mar 25, 2026Since our inception, we have focused substantially all of our efforts and financial resources on research and development activities for…View ↗
The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised…View ↗
For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level…View ↗
$11.8M
10-K for FY2025, filed Mar 25, 2026
$11.8M ↗
Biotechnology companies obtain licenses to Maze’s drug programs through license agreements.
10-K for FY2025, filed Mar 25, 2026Since our inception, we have focused substantially all of our efforts and financial resources on research and development activities for…View ↗
The Company assessed the Trace License Agreement in accordance with ASC 606 and concluded that it was a contract with a customer. The…View ↗
The Company assessed the Shionogi License Agreement in accordance with ASC 606 and concluded that it was a contract with a customer. The…View ↗
The Company assessed the Neurocrine License Agreement in accordance with ASC 606 and concluded that it was a contract with a customer. The…View ↗
No. It lost $131.1M in FY2025.
10-Q for Q3 FY2026, filed Nov 9, 2026
−$48MView ↗
Loading...